In this SOHO Insider interview from EHA 2026, María Díez-Campelo, MD, PhD, hematologist at the University Hospital of Salamanca in Spain, discusses updated phase 2 trial results for elritercept in transfusion-dependent, lower-risk myelodysplastic syndromes.
Dr. Campelo outlines safety and efficacy data for elritercept, a novel TGF-beta pathway inhibitor. In the interview, she provides, patients’ transfusion independence rates and overall response rates, including data in difficult-to-treat patient subgroups.
Leave feedback about this